Qual é o preço para Impact Therap-b (7630)

O preço para Impact Therap-b (7630) é $1.85

Qual é a capitalização de mercado para Impact Therap-b (7630)

A capitalização de mercado para Impact Therap-b (7630) é $510.85M

Histórico de Preços de Impact Therap-b (7630)

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

Ano	Desempenho
Não há dados suficientes para as datas fornecidas.

Ano

Desempenho

Não há dados suficientes para as datas fornecidas.

Empresa	Preço da ação	Variação 1a%	País
Eli Lilly and Company LLY.US	$1.15K	57.34%	US
Johnson & Johnson JNJ.US	$266.36	50.34%	US
AbbVie Inc. ABBV.US	$255.29	21.34%	US
Roche Holding AG RO.SW	$471.58	37.68%	CH
Merck & Co., Inc. MRK.US	$147.38	75.20%	US

Empresa

Preço da ação

Variação 1a%

País